Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS
Cancer Discov. 2014 4 (1): 80-93

PMID: 24265155 · PMCID: PMC3936420 · DOI:10.1158/2159-8290.CD-13-0642

MeSH Terms (25)

Adult Aged Aged, 80 and over Antineoplastic Agents Cell Line, Tumor Clonal Evolution Drug Resistance, Neoplasm Female Humans Imidazoles Indoles Male Melanoma Middle Aged Mitogen-Activated Protein Kinases Oximes Phosphatidylinositol 3-Kinases Protein Kinase Inhibitors Proto-Oncogene Proteins B-raf Proto-Oncogene Proteins c-akt PTEN Phosphohydrolase ras Proteins Skin Neoplasms Sulfonamides Vemurafenib

Connections (3)

This publication is referenced by other Labnodes entities: